Walleye Capital LLC Kodiak Sciences Inc. Transaction History

Walleye Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.29 - $4.48 $23,291 - $45,566	10,171 New	10,171 $23,000
Q3 2023 Nov 14, 2023	BUY	$1.8 - $7.49 $109,987 - $457,668	61,104 New	61,104 $109,000
Q2 2022 Aug 08, 2022	SELL	$5.04 - $9.48 $1.71 Million - $3.22 Million	-339,704 Reduced 95.4%	16,389 $125,000
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $2.4 Million - $30.3 Million	338,328 Added 1904.46%	356,093 $2.75 Million
Q4 2021 Mar 03, 2022	BUY	$80.85 - $128.49 $1.44 Million - $2.28 Million	17,765 New	17,765 $1.51 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.